LETTER

DCK confers sensitivity of DCTD-positive cancer cells to oxidized methylcytidines

  • Ya-Hui Zhao 1 ,
  • Wei Jiang 2 ,
  • Hai Gao 1,3 ,
  • Guo-Zheng Pang 1 ,
  • Yu-Shuang Wu 1 ,
  • Yuan-Xian Wang 1 ,
  • Meng-Yao Sheng 1 ,
  • Jia-Ying Xie 1 ,
  • Wan-Ling Wu 4 ,
  • Zhi-Jian Ji 2 ,
  • Ya-Rui Du 2 ,
  • Lei Zhang 5 ,
  • Xiao-Qin Wang 4 ,
  • Colum P. Walsh 6,7 ,
  • Hai Jiang , 2 ,
  • Guo-Liang Xu , 1,2 ,
  • Dan Zhou , 1,3
Expand
  • 1. Shanghai Key Laboratory of Medical Epigenetics, Laboratory of Cancer Epigenetics, Institutes of Biomedical Sciences, Medical College of Fudan University, Chinese Academy of Medical Sciences (RU069), Shanghai 200032, China
  • 2. State Key Laboratory of Molecular Biology, Institute of Biochemistry and Cell Biology, Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences, Shanghai 200031, China
  • 3. Center for Medical Research and Innovation, Shanghai Pudong Hospital, Fudan University, Shanghai 201399, China
  • 4. Department of Hematology, Huashan Hospital of Fudan University, Shanghai 200040, China
  • 5. Department of Chemistry and Institutes of Biomedical Science, Shanghai Medical College, Fudan University, Shanghai 200032, China
  • 6. Genomic Medicine Research Group, Biomedical Sciences, Ulster University, Coleraine BT52 1SA, United Kingdom
  • 7. Centre for Research and Development, Region Gävleborg/Uppsala University, Gävle SE-801 87, Sweden
hai@sibcb.ac.cn
xugl@fudan.edu.cn
danzhou@fudan.edu.cn

Accepted date: 24 May 2022

Published date: 15 Jul 2023

Copyright

2022 The Author(s) 2022. Published by Oxford University Press on behalf of Higher Education Press.

Cite this article

Ya-Hui Zhao , Wei Jiang , Hai Gao , Guo-Zheng Pang , Yu-Shuang Wu , Yuan-Xian Wang , Meng-Yao Sheng , Jia-Ying Xie , Wan-Ling Wu , Zhi-Jian Ji , Ya-Rui Du , Lei Zhang , Xiao-Qin Wang , Colum P. Walsh , Hai Jiang , Guo-Liang Xu , Dan Zhou . DCK confers sensitivity of DCTD-positive cancer cells to oxidized methylcytidines[J]. Protein & Cell, 2023 , 14(7) : 532 -537 . DOI: 10.1093/procel/pwac028

1
Appelbaum FR, Rowe JM, Radich J, et al. Acute myeloid leukemia. N Engl J Med 1999;341:1051–1062.

DOI

2
Bruno PM, Liu Y, Park GY, et al. A subset of platinum-containing chemotherapeutic agents kills cells by inducing ribosome biogenesis stress. Nat Med 2017;23:461–471.

DOI

3
Ebrahem Q, Mahfouz RZ, Ng KP, et al. High cytidine deaminase expression in the liver provides sanctuary for cancer cells from decitabine treatment effects. Oncotarget 2012;3:1137–1145.

DOI

4
Fugger K, Bajrami I, Dos Santos MS, et al. Targeting the nucleotide salvage factor DNPH1 sensitizes BRCA-deficient cells to PARP inhibitors. Science 2021;372:156–165.

DOI

5
Jamieson GP, Finch LR, Snook M, et al. Degradation of 1-beta-D-arabinofuranosylcytosine 5′-triphosphate in human leukemic myeloblasts and lymphoblasts. Cancer Res 1987;47:3130–3135.

6
Jiang H, Pritchard JR, Williams RT, et al. A mammalian functional- genetic approach to characterizing cancer therapeutics. Nat Chem Biol 2011;7:92–100.

DOI

7
Lin YW, Slape C, Zhang Z, et al. NUP98-HOXD13 transgenic mice develop a highly penetrant, severe myelodysplastic syndrome that progresses to acute leukemia. Blood 2005;106:287–295.

DOI

8
Maley GF, Maley F. The significance of the substrate specificity of T2r+-induced deoxycytidylate deaminase. J Biol Chem 1966;241:2176–2177.

DOI

9
Saba HI. Decitabine in the treatment of myelodysplastic syndromes. Ther Clin Risk Manag 2007;3:807–817.

10
Scarano E. The enzymatic deamination of 6-aminopyrimidine deoxyribonucleotides. I. The enzymatic deamination of deoxycytidine 5′-phosphate and of 5-methyldeoxycytidine 5- methyldeoxycytidine 5′-phosphate. J Biol Chem 1960a;235:706–713.

DOI

11
Scarano E. The enzymatic deamination of 6-aminopyrimidine deoxyribonucleotides. II. Purification and properties of a 6-aminopyrimidine deoxyribonucleoside 5′-phosphate deaminase from unfertilized eggs of sea urchine. J Biol Chem 1960b;235:706–713.

DOI

12
Vilpo JA, Vilpo LM. Nucleoside monophosphate kinase may be the key enzyme preventing salvage of DNA 5-methylcytosine. Mutat Res-Fund Mol M 1993;286:217–220.

DOI

13
Wang L, Gural A, Sun XJ, et al. The leukemogenicity of AML1-ETO is dependent on site-specific lysine acetylation. Science 2011;333:765–769.

DOI

14
Wang T, Yu H, Hughes NW, et al. Gene essentiality profiling reveals gene networks and synthetic lethal interactions with oncogenic ras. Cell 2017;168:890–903.e15e815.

DOI

15
Zauri M, Berridge G, Thézénas ML, et al. CDA directs metabolism of epigenetic nucleosides revealing a therapeutic window in cancer. Nature 2015;524:114–118.

DOI

Outlines

/